This recall touches on medicine manufacturing, regulatory vigilance, and the lived experience of people with neurodivergent brains. Pharmacies, prescribers, and pharmacy benefit managers will need clear guidance so patients can switch formulations or brands without gaps in therapy. Caregivers and patients should feel empowered to ask pharmacists about lot numbers, alternatives, and any signs of reduced effectiveness so they can act promptly and preserve stability in school, work, or home life.
Follow the link to read the full report and learn which lots are involved and what steps regulators recommend. Understanding the details helps families and clinicians protect attention, learning, and wellbeing while we wait for a safe, reliable supply.
Millions of Americans who rely on medication for attention deficit hyperactivity disorder (ADHD) may be affected by a new drug recall. Sun Pharmaceutical Industries has issued a voluntary, nationwide recall for several lots of lisdexamfetamine dimesylate capsules, a generic…